Controlled study of DTIC versus DTIC plus epirubicin in metastatic malignant melanoma

Massimo Lopez, Carlo Federico Perno, Luigi Di Lauro, Paola Papaldo, Fabrizio Ganzina, Aldo Barduagni

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Forty-two previously untreated patients with metastatic malignant melanoma were randomized to receive DTIC at a dose of 250 mg/m2/day 4 IV on days 1-5 or the same drug plus epirubicin (Epi-DX) at a dose of 90 mg/m2 on day 1. Cycles were repeated every 3 weeks. Partial responses were observed in two out of 22 patients (9.1%) treated with DTIC, and in four out of 19 evaluable patients (21.1%) treated with Epi-DX+DTIC. Overall, Epi-DX+DTIC combination was well tolerated, thus permitting administration after a 3-week interval of the full drug dosages in all but two patients. No major cardiotoxicity was observed. Although patients in the Epi-DX+DTIC group had a better response rate than those in the DTIC group, the difference was not statistically significant, and the 21.1% response rate observed with the two-drug combination does not differ from that reported with DTIC used alone.

Original languageEnglish
Pages (from-to)319-322
Number of pages4
JournalInvestigational New Drugs
Volume2
Issue number3
DOIs
Publication statusPublished - Sep 1984

Fingerprint

Epirubicin
Dacarbazine
Melanoma
Drug Combinations
Pharmaceutical Preparations

Keywords

  • chemotherapy
  • DTIC
  • epirubicin
  • malignant melanoma

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Controlled study of DTIC versus DTIC plus epirubicin in metastatic malignant melanoma. / Lopez, Massimo; Perno, Carlo Federico; Di Lauro, Luigi; Papaldo, Paola; Ganzina, Fabrizio; Barduagni, Aldo.

In: Investigational New Drugs, Vol. 2, No. 3, 09.1984, p. 319-322.

Research output: Contribution to journalArticle

Lopez, Massimo ; Perno, Carlo Federico ; Di Lauro, Luigi ; Papaldo, Paola ; Ganzina, Fabrizio ; Barduagni, Aldo. / Controlled study of DTIC versus DTIC plus epirubicin in metastatic malignant melanoma. In: Investigational New Drugs. 1984 ; Vol. 2, No. 3. pp. 319-322.
@article{54855e3b8b414032b4d3f871e7a7ad5a,
title = "Controlled study of DTIC versus DTIC plus epirubicin in metastatic malignant melanoma",
abstract = "Forty-two previously untreated patients with metastatic malignant melanoma were randomized to receive DTIC at a dose of 250 mg/m2/day 4 IV on days 1-5 or the same drug plus epirubicin (Epi-DX) at a dose of 90 mg/m2 on day 1. Cycles were repeated every 3 weeks. Partial responses were observed in two out of 22 patients (9.1{\%}) treated with DTIC, and in four out of 19 evaluable patients (21.1{\%}) treated with Epi-DX+DTIC. Overall, Epi-DX+DTIC combination was well tolerated, thus permitting administration after a 3-week interval of the full drug dosages in all but two patients. No major cardiotoxicity was observed. Although patients in the Epi-DX+DTIC group had a better response rate than those in the DTIC group, the difference was not statistically significant, and the 21.1{\%} response rate observed with the two-drug combination does not differ from that reported with DTIC used alone.",
keywords = "chemotherapy, DTIC, epirubicin, malignant melanoma",
author = "Massimo Lopez and Perno, {Carlo Federico} and {Di Lauro}, Luigi and Paola Papaldo and Fabrizio Ganzina and Aldo Barduagni",
year = "1984",
month = "9",
doi = "10.1007/BF00175384",
language = "English",
volume = "2",
pages = "319--322",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Controlled study of DTIC versus DTIC plus epirubicin in metastatic malignant melanoma

AU - Lopez, Massimo

AU - Perno, Carlo Federico

AU - Di Lauro, Luigi

AU - Papaldo, Paola

AU - Ganzina, Fabrizio

AU - Barduagni, Aldo

PY - 1984/9

Y1 - 1984/9

N2 - Forty-two previously untreated patients with metastatic malignant melanoma were randomized to receive DTIC at a dose of 250 mg/m2/day 4 IV on days 1-5 or the same drug plus epirubicin (Epi-DX) at a dose of 90 mg/m2 on day 1. Cycles were repeated every 3 weeks. Partial responses were observed in two out of 22 patients (9.1%) treated with DTIC, and in four out of 19 evaluable patients (21.1%) treated with Epi-DX+DTIC. Overall, Epi-DX+DTIC combination was well tolerated, thus permitting administration after a 3-week interval of the full drug dosages in all but two patients. No major cardiotoxicity was observed. Although patients in the Epi-DX+DTIC group had a better response rate than those in the DTIC group, the difference was not statistically significant, and the 21.1% response rate observed with the two-drug combination does not differ from that reported with DTIC used alone.

AB - Forty-two previously untreated patients with metastatic malignant melanoma were randomized to receive DTIC at a dose of 250 mg/m2/day 4 IV on days 1-5 or the same drug plus epirubicin (Epi-DX) at a dose of 90 mg/m2 on day 1. Cycles were repeated every 3 weeks. Partial responses were observed in two out of 22 patients (9.1%) treated with DTIC, and in four out of 19 evaluable patients (21.1%) treated with Epi-DX+DTIC. Overall, Epi-DX+DTIC combination was well tolerated, thus permitting administration after a 3-week interval of the full drug dosages in all but two patients. No major cardiotoxicity was observed. Although patients in the Epi-DX+DTIC group had a better response rate than those in the DTIC group, the difference was not statistically significant, and the 21.1% response rate observed with the two-drug combination does not differ from that reported with DTIC used alone.

KW - chemotherapy

KW - DTIC

KW - epirubicin

KW - malignant melanoma

UR - http://www.scopus.com/inward/record.url?scp=0021125383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021125383&partnerID=8YFLogxK

U2 - 10.1007/BF00175384

DO - 10.1007/BF00175384

M3 - Article

VL - 2

SP - 319

EP - 322

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -